



Liver Forum 15

September 6, 2023

Institut Pasteur

Veronica Miller, PhD Director



Wi-Fi Access





Passcode:





Please ensure your phone is turned to Silent or Vibrate Mode



Session I: Welcome & Introductory Remarks

Veronica Miller, Forum for Collaborative Research Arun Sanyal, Virginia Commonwealth University Judith Ertle, Boehringer Ingelheim

Overview of the Liver Forum

- What: a platform for <u>ongoing</u> multi-stakeholder dialogue to identify barriers, prioritize research and identify solutions to accelerate therapeutic development for NAFLD/NASH
- How: provide a neutral, independent, safe space for discussion and deliberation across stakeholder groups
 - Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
 - Ongoing working group activity throughout the year anchored by larger project events
 - Active & engaged participation





Forum Operating Principles

- Independent and neutral venue
 - Ongoing multi-stakeholder dialogue
 - Each stakeholder group has an equal voice
- Facilitate best science-based decisions, in real time
 - Break down inefficiencies and redundancy
 - Increase clarity, collaboration and innovation
 - Benefit to whole field, especially patients





Forum = Safe Space

- Closed meeting
 - No marketing
 - No press
- Bring your expertise
 - Leave your "hat" at the door



Rules of the Room and Zoom



What's said in the room, stays in the room

What's said in the room, is not for attribution

Let the science speak

Active participation



Steering Committee



Co-Chairs

Veronica Miller Forum for Collaborative Research

Arun Sanyal, *Virginia Commonwealth University*

Judith Ertle, Boehringer Ingelheim

Ruby Mehta, FDA/ CDER/ DHN

Regulatory

Joachim Musaus *European Medicines Agency*

Charmaine Stewart, FDA/CDER/DHN

Donna Cryer, Global Liver Institute

Patient Advocates

Consortia

Society

Wayne Eskridge Fatty Liver Foundation

Lorraine Stiehl

American Liver Foundation

Quentin Anstee, LITMUS

Sudha Shankar, NIMBLE

Naga Chalasani, AASLD

Annalisa Berzigotti, EASL

Manal Abdelmalek, Mayo Clinic

Mazen Noureddin, Houston Research Institute

Jörn Schattenberg, *University Medical Center Mainz*

Brent Tetri, Saint Louis University

Stavra Xanthakos

Cincinnati Children's Hospital Medical Center

Michelle Long, Novo Nordisk

Margery Connelly, LabCorp

Céline Fournier, *Echosens*

Melissa Palmer, Liver Consulting LLC

David Shapiro, Industry Consultant

Industry

Academia



Liver Forum Sponsors



































































































Forum Team



- Veronica Miller Director
- Brenda Rodriguez Deputy Director
- Azza Karrar Senior Research Associate
- Logan Donaldson Research Associate
- Sehyr Khan Research Associate
- Mitchell Leus Research Associate
- Shilpa Mitra Research Associate
- Nicholas Murdock Research Associate
- Alicia Jellinek Program Financial Analyst
- Christopher Berry Events Manager
- Donnice Butler Senior Administrative Assistant

- Robin Schaefer Postdoctoral Scholar
- Chris Hoffman IT and Operational Director
- Margot Yann Lead Data Scientist
- Zachary Rooney Research Associate
- Sammy Berman Research Data Analyst
- Jeffrey S. Murray Program Advisor
- John Sninsky Program Advisor
- Alessi Ayvaz Student Researcher
- Danielle Howard Stewart Graduate Student Researcher
- Andriana Marijic Buljubasic Graduate Student Researcher







Review of Liver Forum 15 Goals and Objectives

Veronica Miller, Forum for Collaborative Research





Goals for Today

- Develop clarity on MASLD/MASH nomenclature -- drug development
 - Regulatory, industry, patient perspectives
 - In collaboration with AASLD and EASL
- Support transition to non-invasive approach to MASH
- Stimulate new thinking re diagnostics
- Update on working group activities
 - Life/soul of LF!
- LBNL: Walk away with new insights, colleagues and collaborations!



Session II: Steatotic Liver Diseases: Review of New Nomenclature from Multi-Stakeholders Perspectives

Moderators:

Veronica Miller, Forum for Collaborative Research
Jörn Schattenberg, University Medical Center Mainz



Journal Pre-proof

A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart Koot, Marko Korenjak, Kris Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth Powell, Michael Roden, Manuel Romero-Gómez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome, senior, on behalf of the NAFLD Nomenclature consensus group





Recipient First Name	Recipient Last Name	Country
Manal	Abdelmalek	United States
Leon	Adams	Australia
Veeral	Ajmera	United States
Mamun	Al Mahtab	Bangladesh
William	Alazawi	United Kingdom
Maryam	Alkhatry	United Arab
		Emirates
Naim	Alkhouri	United States
Alina	Allen	United States
Michael	Allison	United Kingdom
Khalid	Alswat	Saudi Arabia
Michele	Alves-Bezerra	United States
Quentin	Anstee	United Kingdom
Juan Pablo	Arab	Canada
Matthew J.	Armstrong	United Kingdom
Marco	Arrese	Chile
Diego	Arufe	Argentina
Pablo	Aschner	Colombia
Amon	Asgharpour	United States
Gyorgy	Baffy	United States
Maya	Balakrishnan	United States
Meena	Bansal	United States
Pierre	Bedossa	United States
Cynthia	Behling	United States
Renata	Belfort	United States
Carlos	Benítez	Chile
Thomas	Berg	Germany
Annalisa	Berzigotti	Germany
Michael	Betel	United States
Ulrich	Beuers	Netherlands
Cristiana	Bianco	Italy
Jerome	Boursier	France
Clifford	Brass	United States
Carol L.	Brosgart	United States
Elizabeth Matthews	Brunt	United States
Elisabetta	Bugianesi	Italy
Maria	Buti	Spain
Christopher	Byrne	United Kingdom
Steve	Caldwell	United States
Rotonya	Carr	United States
Teresa	Casanovas	Spain
Marlene	Castellanos-Fernández	Cuba

Laurent	Castera	France
Graciela	Castro-Narro	México
Cyrielle	Caussy	France
Eira	Cerda	México
Naga	Chalasani	United States
Wah Kheong	Chan	Malaysia
Phunchai	Charatcharoenwitthaya	Thailand
Michael	Charlton	United States
Amanda	Cheung	United States
Daniela	Chiodi	Argentina
Ray	Chung	United States
David	Cohen	United States
Kathleen	Corey	United States
Helena	Cortez-Pinto	Portugal
Helma P.	Cotrim	Brazil
Javier	Crespo	Spain
Deborah	Crosby	United States
Donna	Cryer	United States
Kenneth	Cusi	United States
Yock Young	Dan	Singapore
Anuradha	Dassanavake	Sri Lanka
Nicholas	Davidson	United States
Robert	De Knegt	Netherlands
Victor	De Ledinghen	France
Münevver	Demir	Germany
Moutaz	Derbala	Qatar
Sebastian	Diaz	Colombia
Anna Mae	Diehl	United States
Bruce	Dimmig	United States
Melisa	Dirchwolf	Argentina
Ajay	Duseja	India
Karel	Dvorak	Prague
Mattias	Ekstedt	Sweden
Reda	El Wakil	Egypt
Mohammed	El-Kassas	Egypt
Wayne	Eskridge	United States
Jiangao	Fan	China
Geoffrey	Farrell	Australia
María Lucía	Ferraz	Brazil
Yasser	Fouad	Egypt
Sven	Francque	Belgium
Dave	Frank	United States
Scott	Friedman	United States
Angie	Fry Carpenter	United States
Michael	Fuchs	United States
Rino	Gani	Indonesia

Amalia	Gastaldelli	Italy
Anja	Geerts	Belgium
Andreas	Geier	Germany
Marcos	Girala	Paraguay
George	Goh	Singapore
Nicolas	Goossens	Switzerland
Cheryl	Grainger	United States
Isabel	Graupera	Catalonia
Cynthia	Guy	United States
Hannes	Hagström	Sweden
Stephen	Harrison	United States
Zachary	Henry	United States
Bela	Hunyady	Hungary
Alan	Hutchison	United States
Scott	Isaacs	United States
Jidong	Jia	China
François	Jornayvaz	Switzerland
Fasiha	Kanwal	United States
Cynthia	Kemp	United States
Denise	Kile	United States
Won	Kim	South Korea
Seung Up	Kim	South Korea
George	KK Lau	Hong Kong
Samuel	Klein	United States
David	Kleiner	United States
Rohit	Kohli	United States
Bart	Koot	Netherlands
Yannoula	Koulla	Cyprus
Marcelo	Kugelmas	United States
Joel	Lavine	United States
Jeffrey	Lazarus	Spain
Mariana	Lazo	United States
Hye Won	Lee	South Korea
Nathalie	Leite	Rio de Janeiro
Han-Chieh	Lin	Taiwan
Michelle	Long	United States
Rohit	Loomba	United States
Susan	Love Hawfield	United States
Adelina	Lozano	Peru
Panu	Luukkonen	Finland
Paula	Macedo	Portugal
Dina	Mansour	United Kingdom
Christos	Mantzoros	United States
Giulio	Marchesini	Italy
Sebastián	Marciano	Buenos Aires



Claudia P.	Marques Souza de	Brazil
	Oliveira	
Kim	Martinez	United States
Lyudmila Vladimirova	Mateva	Bulgaria
Jose M	Mato	Spain
Alexis	McCary	United States
Jeff	McIntyre	United States
Luca	Miele	Italy
Ivana	Mikolasevic	Croatia
Veronica	Miller	United States
Pam	Miller	United States
Maria "Terri"	Milton	United States
Milan	Mishkoviki	North Macedonia
Robert	Mitchell-Thain	United Kingdom
Rosalba	Moreno	United States
Timothy	Morgan	United States
Cynthia	Moylan	United States
Atsushi	Nakajima	Japan
Jean Charles	Nault	France
Phil	Newsome	United Kingdom
Suzanne	Norris	Ireland
Mazen	Noureddin	United States
Claudia P.	Oliveira	Brazil
Massao	Omata	Japan
Arlin	Ong	Philippines
Martín	Padilla	Perú
Raluca	Pais	France
Arturo	Panduro	Mexico
Manas K	Panigrahi	India
	Papatheodoridis	Greece
George Edison	Parise	Brazil
Sonali	Paul	United States
Diana	Payawal	Philippines
Serena	Pelusi	Italy
Marlene	Pérez	Brazil
Juanita	Perez Escobar	Mexico
Gianluca	Perseghin	Italy
Mario Salvatore	Pessoa Petta	Brazil
		Italy
Massimo	Pinzani	United Kingdom
Monica	Platon Lupsor	Romania
Atoosa	Rabiee	United States
Vlad	Ratziu	France
Mario R.	Alvares-da-Silva	Brazil
Mary	Rinella	United States
Michael	Roden	Germany

Stefano	Romeo	Sweden
Manuel	Romero Gomez	Spain
Yaron	Rotman	United States
lan	Rowe	United Kingdom
Riina	Salupere	Estonia
Arun	Sanyal	United States
Shiv Kumar	Sarin	India
Sanjaya K.	Satapathy	United States
Jörn M.	Schattenberg	Germany
Wendy	Schaufert	Canada
Bernd	Schnabl	United States
Jeff	Schwimmer	United States
Lynn	Seim	United States
Lawrence	Serfaty	France
David	Shapiro	United States
Marcelo	Silva	Buenos Aires
Ashwani K.	Singal	United States
Shivaramn Prasad	Singh	India
Lubomir	Skladany	Slovakia
Silvia	Sookoian	Argentina
Norbert	Stefan	Germany
Jonathan	Stine	United States
Shikha	Sundaram	United States
C. Wendy	Spearman	South Africa
Gianluca	Svegliati-Baroni	Italy
Gyonzgi	Szabo	United States
Frank	Tacke	Germany
Tawesak	Tanwandee	Thailand
Giovanni	Targher	Italy
Brent	Tetri	United States
Maja	Thiele	Denmark
Dina	Tiniakos	Greece
Baron	Tisthammer	United States
Aldo	Torre Delgadillo	Mexico
Diane	Tovar	United States
Michael	Trauner	Austria
Emmanuel	Tsochatzis	United Kingdom
Luca	Valenti	Italy
Laurens	Van Kleef	Netherlands
Saskia	Van Mil	Netherlands
Lisa	VanWagner	United States
Adriana	Varon Puerta	Colombia
Jose Antonio	Velarde Ruiz Velasco	Mexico
Mette	Vesterhus	Norway
Eduardo Anthony	Vilar-Gomez Villiotti	United States United States
Anthony	VIIIIOtti	United States



Miriam	Vos	United States
Kymberly	Watt	United States
Julia	Wattacheril	United States
Fonda	Wilkins	United States
José	Willemse	Netherlands
Vincent	Wong	China
Stavra	Xanthakos	United States
Yusuf	Yilmaz	Turkey
Lorna	Younger	United States
Zobair	Younossi	United States
Amany	Zekry	United Kingdom
Shira	Zelber-Sagi	Israel






Panel Discussion


Panelists:

- Arun Sanyal, Virginia Commonwealth University
- Meena Bansal, Mount Sinai Hospital, NY
- Sven Francque*, University of Antwerp, Belgium
- George Makar*, US Food and Drug Administration (FDA)
- Joachim Musaus, European Medicines Agency (EMA)
- Don Chalfin, Patient
- Henry Chang*, Fatty Liver Foundation
- Michelle Long, NovoNordisk
- Judith Ertle, Boehringer Ingelheim






General Discussion



Session III: Advances in Digital Pathology & Al/ML for MASH


Moderator: Arun Sanyal, Virginia Commonwealth





Dean Tai, HistoIndex








Janani Iyer & Katy Wack*, PathAl








Mathieu Petitjean, PharmaNest









Cindy Serdjebi, BioCellvia





General Discussion



Coffee Break

Wi-Fi Access



Network:


Passcode:





Please ensure your phone is turned to Silent or Vibrate Mode






Session IV: Moving Forward with NITs

Moderators:

Laurent Castera, Université Paris Cite Hôpital Beaujon Meena Bansal, Mount Sinai Hospital, NY





Brief Overview of Liver Forum Work in NITs

Veronica Miller, Forum for Collaborative Research



COMMENTARIES

Baseline (Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

regulatory agencies, the pharmaceutical and medical diagnostics industries, and patient advocacy organizations to develop consensus recommendations for standardized baseline parameters for NASH-related clinical trials.

Methods

A working group of the Liver Forum assessed the state of the science in clinical trials for NASH and made specific recommendations for the categories of data to

NAFLD fibrosis p morbid condition cular disease. Ag include decrease and mitochondri and ethnicity, oft known genetic considered importante for proof phase II trials, and essential componals. These are t given the curren

Gastro enterology 2017;153:621-625

Supplementary Materials

Comorbidities & Surgical History Anthropometrics Specialized Biomarkers Health Related Quality of Life

Table 1. Metabolic Panel

	Early Phase Trials	Late Phase Trials
Fasting glucose Fasting insulin Hemoglobin A1c HOMA Glucose clamp OGTT	EECCC	E E C NR C

C, consider; E, essential; HOMA, homeostasis model assessment; NR, not recommended; OGTT, oral glucose tolerance test.


Table 2 Laboratory Tests

	Early Phase Trials	Late Phase Trials
ALT	E	E
AST	E	E
ALP	E	E
Total bilirubin	E	E
Direct bilirubin	E	E
GGT	E	E
Albumin	E	E
Profirombin time or INR	E	E
Total cholesterol	E	E
LDL-C	E	E
HDL-C	E	E
TSH	E	E
Triglycerides	E	E
Hemoglobin	E	E
Hematocrit	E	E
Platelets	E	E
BUN	E	E
Creatinine	E	E
Urine microalbumin	C	C
Ferritin	1	



- LF12
 - Review diagnostic and prognostic NITs
- LF14
 - Review treatment response NITs








FDA NIT Workshop: Open Invitation

Abbas Bandukwala*, US Food and Drug Administration







Proposal to the Liver Forum

Quentin Anstee*, Newcastle University



Meta-Thoughts on Response Biomarkers in NASH Drug Development





- In the absence of a single 'gold standard' biomarker, undertake a wholistic assessment of biomarker response and demonstrate change at the patient level.
- We should agree and define a common set of biomarkers that will be measured and reported in all future clinical trials.

Quentin Anstee LF12



																			Ц						
	Trial Phase	Pha	ise Ila	/IIb																					
	Year	2018	2020	2021	2021	2022	2019	2019	2021	2021	2020	2020	2021	2021	2022	2020	2016	2020	2020	2021	2015	2020	2021	2018	2020
	Duration	12	12	12	12	12	12/36	16	16	16	24	24	24	24	24/48	48	52	52	52	52	72	72	72	96	104
		Aldafermin	Aldafermin	TVB-2640 (FASCINATE 1)	Tern-101 (LIFT)	EDP-305 (ARGON-1)	Resmetirom (MGL-3196-05)	Pegbelfermin (FGF21)	Efruxifermin (BALANCED)	Saroglitazar (EVIDENCES IV)	Cilofexor	Combination (ATLAS)	Lanifibranor (NATIVE)	Aldafermin (ALPINE 2/3)	Pegbelfermin (FALCON 1/2)	Tropifexor (FLIGHT-FXR)	Elafibranor (GOLDEN-505)	Seladelpar	MSDC-0602K (EMMINENCE)	Aramchol (ARREST)	OCA (FLINT)	Emricasin	Semaglutide	Sim tuzumab	CVC (CENTAUR)
Clinical Chemistry	ALT & AST	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	√	✓	✓	√	✓	✓	✓	√
Ī	APRI									✓	✓				✓				✓						✓
Simple Scores Indirect Biomarkers	NFS					✓									✓		✓			✓				✓	
ndirect Biomarkers	FIB4					✓					✓		✓		✓				✓	✓					✓
	CK18			✓			✓			✓	✓	✓	✓					✓	✓			✓	✓		
	ELF	✓	✓	?			✓		✓	✓	✓	✓	✓	✓	✓				✓	✓			✓	✓	✓
Direct Biomarkers	Fibrotest										✓						✓		✓					✓	
	PRO-C3	✓	✓	✓			✓	✓	✓				✓	✓	✓										✓
Fibroscan	VCTE								✓	✓	✓	✓			✓								✓		
Fibioscan	FAST											✓											✓		
	MR-PDFF	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓		✓		✓					
MR	MR-cT1		✓		✓																				
	MRE							✓			✓	✓			✓										
Liver Biopsy	Histology		✓	✓			✓		✓				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓








Panel Discussion

Panelists:


- Manal Abdelmalek*, Mayo Clinic
- Vlad Ratziu, Sorbonne Université
- Claudia Filozof, Fortrea
- Corinna Schoelch, Boehringer Ingelheim
- Michael Betel, Fatty Liver Alliance
- Michael Middleton, UC San Diego





Session V: Stretch Exercise: Pragmatic Benefit-Risk Assessment for Diagnostics

Moderator: Veronica Miller, Forum for Collaborative Research







A New Look at Benefit-Risk in Diagnostics

Scott Evans, George Washington University






General Discussion



Session VI: Working Group Updates and Proposals






MASH (NASH) Placebo Arm Database

Michael Cooreman, Inventiva Pharma








Combination Therapy

Michelle Long, Novo Nordisk








Pooling of Endpoints Across Trials

Michelle Long, Novo Nordisk








Discussant

Laurent Castera, Université Paris Cite Hôpital Beaujon








New Working Group: Radiology Liver Diseases (RLD) Program

Michael Middleton, UC San Diego








New Working Group: Intersection of Steatotic Liver Disease (SLD) and Alcohol Liver Disease (ALD)- Met-ALD

Nikhil Vergis, GlaxoSmithKline







Discussants

Donna Cryer, Global Liver Institute **Roberto Calle*,** Regeneron





Closing Remarks

- Arun Sanyal, Virginia Commonwealth University
- Judith Ertle, Boehringer Ingelheim
- Veronica Miller, Forum for Collaborative Research

Liver Forum Sponsors





































































































LF 15 Evaluation & Working Groups Sign up

 Use the QR codes provided for you in your participant folder to complete the evaluation and sign up for the new working groups





Adjourn and Networking Reception